Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)

NCT07788677 is registered in ClinicalTrials.gov with Vall d'Hebron Institute of Oncology as lead sponsor.

NCT NCT07788677
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07788677 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tarlatamab Treatment Before and After Surgery in Surgically Resectable Recurrent High-grade Glioma: a Window of Opportunity Study (TARLAGLIA Study)
Lead sponsor
Vall d'Hebron Institute of Oncology
Phase
Phase 1
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
May 1, 2029
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high-grade glioma (hgg)